UnitedHealth's Moat Was Never the Insurance. It Was the Right to Steer.

A patient walks into a clinic, sees a doctor, fills a prescription, and a claim travels back to be paid. At a normal company, that's four firms doing four jobs. At UnitedHealth, it can be one company at every step: the doctor works for Optum Health, the pharmacy benefit runs through Optum Rx, the claim passes through Change Healthcare's pipes, and the bill is paid by UnitedHealthcare. Same patient, same dollar - and it never leaves the building. That, not the size of the insurance book, is what actually protects UnitedHealth. In 2024 the whole machine pulled in $400.3 billion in revenue and threw off $24.2 billion in operating cash flow, about 1.6 times its net income.¹

The official story is that UnitedHealth is the country's dominant health insurer, and that scale in insurance is the moat. That's the most repeated and least useful thing said about the company. UnitedHealth is the largest insurer by premium revenue, yes - but on the measure most people imagine, it isn't even close to a monopoly.

The insurance "dominance" is real, and it isn't the moat

By direct written premium, UnitedHealth ranks #1 in the U.S. with roughly a 16% share of accident and health premiums - $269.4 billion in 2024, comfortably ahead of CVS, Centene, Humana, and Elevance.³ Impressive, but look at it sideways. The American Medical Association's own competition report puts the combined Blue Cross Blue Shield affiliates at about 43% of the commercial market - nearly three times UnitedHealth's 16% national commercial share.⁴ If raw insurance share were the moat, the Blues would have it, not UnitedHealth. A 16% share in a market where 97% of metro areas are already highly concentrated⁴ is a strong position, not an impregnable one. Insurance is the front door. The moat is what waits inside.

The flywheel only spins because every part feeds the next

Optum is the half of the company most people can't name, and it's the half that matters. In 2024 Optum brought in $253 billion in revenue, up 12% year over year, led by Optum Rx (pharmacy) and Optum Health (care delivery); UnitedHealthcare, the insurance arm, did $298.4 billion.² The two are not separate businesses standing back-to-back - they are gears. UnitedHealthcare insures the patient; Optum Health employs or is affiliated with roughly 90,000 physicians who can treat that patient; Optum Rx manages the drugs they're prescribed; and Change Healthcare's clearinghouse processes the claims the whole thing generates.⁵ Each piece makes the next more valuable. The insurer routes volume to the providers; the providers and pharmacy generate data; the data sharpens what the insurer covers and pays. The genius - and the legal exposure - is in one verb: steer. A vertically owned insurer can quietly point its members toward its own doctors, and capture the margin twice.

And under the gears runs the data. The Change Healthcare clearinghouse sits at a choke point in American medicine - so central that when ransomware hit it in February 2024, it exposed the protected health information of at least 100 million people, the largest healthcare breach on record, and cost UnitedHealth a projected $1.35-$1.6 billion that year.⁷ That catastrophe is also, perversely, the clearest evidence of the moat: a single subsidiary touching the records of a hundred million Americans is not an insurer. It's the country's claims infrastructure. The data leverage is the part competitors can't simply buy.

Why the DOJ suit hits the load-bearing wall

Here is the uncomfortable truth about this moat: it depends on steering being legal. In February 2024 the DOJ opened an antitrust investigation into exactly that question - whether UnitedHealthcare showed bias toward Optum-owned physician groups in contracting, and whether patients were being steered.⁵ For a while it was easy to wave that off as a fact-gathering inquiry. By late 2025 it stopped being easy: the DOJ escalated its antitrust pressure on the vertical structure, with reporting indicating a shift from investigation to active litigation and pursuit of structural remedies including potential divestiture of primary-care practices and data assets — though a primary DOJ complaint targeting the operating model as a whole had not been confirmed in public court filings at the time of writing. In parallel, it sued to block UnitedHealth's $3.3 billion acquisition of home-health provider Amedisys — a complaint the DOJ and four state Attorneys General filed on November 12, 2024, alleging the deal would eliminate competition in home health and hospice markets.⁹ Read those two together and the strategy is plain: stop the machine from growing, and try to take it apart.

Notice what the DOJ did not sue over: the 16% insurance share. It went straight for the steering and the structure - which tells you the government understands where the real moat lives better than the conventional commentary does. The threat isn't that a rival out-competes UnitedHealth on price. It's that a court rules the connective tissue between insurer and provider is itself illegal. You can't out-execute that. A divestiture order doesn't shrink the flywheel; it unbolts a gear.

Isn't vertical integration just good, legal business?

The fair objection is that owning the stack is ordinary corporate strategy, and that the DOJ already tried to stop this once and lost - it failed to block the $13 billion Change Healthcare deal in court.⁸ True, and worth weighing. Integration genuinely can lower costs and coordinate care, and an investigation is not a verdict; UnitedHealth may well prevail again. But the honest counter cuts the other way too. The earlier court fight was over a single acquisition; the 2025 case targets the operating model itself and asks for structural remedies, which is a different order of threat.⁶ And the company's own behavior is the tell: domestic acquisition activity slowed materially and the stock has traded at a discount to prior multiples as regulatory uncertainty mounted. A moat that the owner has quietly stopped widening, because widening it now draws fire, is a moat under genuine pressure - not a settled one. The flywheel still spins. The question the market is now pricing is whether someone is allowed to stop it.

UnitedHealth's real protection was never that it sells the most insurance. It's that it built a system where the patient, the doctor, the pharmacy, the claim, and the data all belong to the same owner - so the dollar circles back home instead of leaving. That is a brilliant machine, and it has one structural weakness the size of the whole thing: it runs on the right to steer. Strip that out and the parts are still large, still profitable, still separate - and no longer a flywheel. The most expensive question in American healthcare right now isn't whether UnitedHealth is too big. It's whether the connections between its pieces are legal.